Solithera Pharmaceuticals: Joining hands with Kaituo Biotech to advance the research and development of in vivo CAR-T/NK therapy using tLNP delivery.

Sillu Dee Pharmaceuticals announced that on August 20, 2025, the company signed a strategic cooperation framework agreement with Kaituo Biological. According to the agreement, based on Sillu Dee Pharmaceuticals' AI+mRNA research and development platform and lipid nanoparticle delivery system, along with Kaituo Biological's advantages and experience in mRNA large-scale production, the two parties will deepen cooperation in the fields of targeted LNP delivery, cancer vaccines, and in vivo CAR-T/NK, among others. This collaboration marks Sillu Dee Pharmaceuticals' continuous acceleration in the layout of mRNA research, providing solid capacity guarantee for the subsequent clinical development and future commercialization of innovative therapeutic products based on mRNA-LNP technology.